Embraer's Order Momentum Extends, but Valuation and Execution Risks Remain Central

What happened

Embraer's stock has surged 20% over the past four months, driven by Azorra's June order that lifted total E2 program orders past 500, three C-390 orders from Greece, and record Q2 deliveries. This momentum comes after the company ended 2025 with a record $31.6B backlog and +18% delivery growth, validating strong demand but leaving execution as the key variable. The optimism is tempered by the stock's elevated valuation (41.6x P/E and 14.3x EV/EBITDA at $64.28 as of late 2025) and the master report's assessment that no margin of safety exists at those levels. Core risks persist: commercial backlog concentration (90.9% of E175 orders from three U.S. operators), prior customer distress like Azul's Chapter 11 reset, and reliance on production leveling to reduce delivery seasonality. While the new orders and deliveries suggest momentum may continue, they do not yet confirm that 2026 will outperform the base case of mid-single-digit delivery growth with stable margins.

Implication

The recent rally has likely pushed the stock closer to the $80 trim threshold identified in the master report, indicating that upside is now limited without a broader repricing of execution certainty. The new Azorra order and Greek C-390 orders are positive but incremental; they do not materially alter the backlog concentration or the supply-chain constraints that gate deliveries. Record Q2 deliveries may reflect some improvement in production leveling, but it is too early to declare victory given historical 4Q bunching and the need for sustained cadence across 1H and 2H. Additionally, the GTF engine reliability risk remains active, and any new customer renegotiation beyond Azul would sharply undermine the bullish narrative. A more prudent approach is to wait for either a pullback toward $55 (attractive entry) or clear evidence of stable commercial backlog and improved delivery evenly distributed through 2026, as the current price embeds an execution premium.

Thesis delta

The core investment thesis—waiting for evidence of production leveling and customer stability before paying up—remains intact. New orders and deliveries are positive signals but do not yet confirm that 2026 will meet the base case, and the stock's recent 20% surge has likely eroded the margin of safety further. Maintain WAIT, with a trim above $80.